Devopharma ApS
CVRCVR number38968254
Company financials
Key figures
Updated 10 Jul 2026
- Return on assets
- -3.1%
- Return on equity
- -12.5%
- Current ratio
- 66.7%
- Equity ratio
- 25%
Profit and loss
| Reporting period | |
|---|---|
Gross profit | -3,125 |
Operating profit | -3,125 |
Finance income | 0 |
Finance expenses | 0 |
Tax expense | 0 |
Profit/loss for the year | -3,125 |
Employees
| Reporting period | |
|---|---|
Avg. employees | 0 |
Personnel costs | 0 DKK |
Balance sheet
| Reporting period | |
|---|---|
Cash and cash equivalents | 0 |
Current assets | 50,000 |
Non-current assets | 50,000 |
Total assets | 100,000 |
Equity | 25,000 |
Liabilities | 75,000 |
Current liabilities | 75,000 |
Capital and dividend
| Reporting period | |
|---|---|
Contributed capital | 50,000 |
Retained earnings | -25,000 |
Proposed dividend recognised in equity | 0 |
Investments and assets
| Reporting period | |
|---|---|
Long-term investments and receivables | 50,000 |
Annual report highlights
Official annual report · 2025
Business and development
Management review (fallback)
Præsentation af virksomheden
Selskabets formål er at udøve virksomhed med forskning og eksperimentel udvikling inden for bioteknologi.…
Risks and material matters
Significant events after the reporting period
Der er efter regnskabsårets afslutning ikke indtruffet begivenheder, der væsentligt vil kunne påvirke vurderingen af selskabets finansielle stilling.
Create a free account to see up to 9 years of financial history
Create free account